Fig. 1: Clinical trials involving plerixafor, and comparison of plerixafor vs AMD11070. | Communications Biology

Fig. 1: Clinical trials involving plerixafor, and comparison of plerixafor vs AMD11070.

From: Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization

Fig. 1

a Overview of the types of clinical trials where plerixafor have been tested. The numbers in brackets show the number of trials within the different therapeutic areas. In scientific literature, plerixafor is also known as AMD3100. The drug is used under the trade name Mozobil. This image was created by Anna Sofie Husted using Adobe illustrator and photoshop under the licence of University of Copenhagen. b Chemical structures of plerixafor and AMD11070. The values below show their binding affinity for CXCR4 measured as their ability to inhibit CXCL12 binding in competitive binding22, their ability to inhibit viral replication in MT-4 cells infected with the HIV-1 strain21, and their ability to block migration of the A375 melanoma cell line towards CXCL12 (10 nM)23.

Back to article page